Cash and cash equivalents totaled $23.2 million as of December 31, 2023, compared to $41.8 million as of December 31, 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
- Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
- Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
- Theriva Biologics VIRAGE Trial Progresses Positively
- Theriva Biologics Reports Positive Phase 2b Trial Progress
